Mast Therapeutics (NYSEMKT:MSTX) reported a rise of 39.3% or 2,850,004 shares in its short interest. The short figure came in at 5.3% of the total floats. The average daily volume of 4,366,067 shares suggests that the days to cover 10,098,156 short positions, as on June 15,2016, will be 2. On May 31,2016, the short interest was 7,248,152 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Mast Therapeutics (NYSEMKT:MSTX): The stock opened at $0.42 on Friday but the bulls could not build on the opening and the stock topped out at $0.46 for the day. The stock traded down to $0.42 during the day, due to lack of any buying support eventually closed down at $0.45 with a loss of -1.47% for the day. The stock had closed at $0.46 on the previous day. The total traded volume was 3,304,002 shares.
The company shares have dropped -4.26% from its 1 Year high price. On Sep 30, 2015, the shares registered one year high at $0.60 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $0.37 and the 200 Day Moving Average price is recorded at $0.35.
Mast Therapeutics (NYSEMKT:MSTX) has climbed 5.07% in the past week and advanced 33.77% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 6.81% and the outperformance has advanced to 37.82% for the last 4 weeks period.
Mast Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops therapies for serious or life-threatening diseases with unmet needs. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, the Companys lead product candidate. Vepoloxamer is being tested in a Phase III clinical study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. AIR001 is being tested in multiple institution-sponsored Phase IIa clinical studies that provide the Company with data on AIR001s potential to treat patients with preserved ejection fraction (HFpEF).